NuVasive, Inc.

476 articles about NuVasive, Inc.

• NuVasive Announces Second Quarter 2020 Financial Results

  8/4/2020

   NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2020.

• NuVasive's Less Invasive Procedural Solutions Are Clinically Proven to Reduce Operative Time and Improve Patient Outcomes in Spine Surgery

  7/22/2020

  Company launches Time to Evolve campaign to equip surgeons and hospital systems with tools and resources to support their evolution to less invasive surgical techniques

• NuVasive Announces Certain Preliminary Unaudited Second Quarter 2020 Results

  7/20/2020

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced certain preliminary unaudited results for the second quarter 2020.

• NuVasive Expands Complex Spine Portfolio with Global Launch of Reline 3D for Pediatric Deformity

  6/18/2020

   NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the expansion of

• NuVasive, Inc. Announces Full Exercise Of Option By Initial Purchasers To Purchase Additional 1.00% Convertible Senior Notes Due 2023

  6/4/2020

  NuVasive, Inc. (NASDAQ: NUVA) announced today that it closed the issuance of an additional $50.0 million in aggregate principal amount of the 1.00% Convertible Senior Notes due 2023 (the "Convertible Notes"), pursuant to the exercise in full of the initial purchasers' option to purchase such additional notes

• NuVasive, Inc. Announces Pricing Of Offering Of $400 Million Of 1.00% Convertible Senior Notes Due 2023

  5/28/2020

  NuVasive, Inc. announced the pricing of its offering of $400.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2023 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• NuVasive, Inc. Announces Proposed Offering Of $400 Million Of Convertible Senior Notes Due 2023

  5/26/2020

  NuVasive, Inc. announced that it intends to offer, subject to market and other considerations, $400.0 million aggregate principal amount of Convertible Senior Notes due 2023 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• NuVasive LessRay® Platform Wins Best New Imaging Technology Solution in 2020 MedTech Breakthrough Awards

  5/19/2020

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its LessRay® radiation reduction and workflow enhancement platform won the "Best New Imaging Technology Solution" award in the 2020 MedTech Breakthrough Awards.

• NuVasive to Participate in UBS Virtual Global Healthcare Conference

  5/12/2020

  NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced that management will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19 at 3:00 p.m. ET/12:00 p.m. PT.

• NuVasive Announces First Quarter 2020 Financial Results

  5/6/2020

  NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced financial results for the quarter ended March 31, 2020.

• NuVasive Expands Advanced Materials Science™ Implant Portfolio to Additional Thoracolumbar Procedures

  5/5/2020

  NuVasive, Inc. announced the expansion of its Advanced Materials Science™ implant portfolio with the commercial launch of the Modulus® XLIF® Dual Sided Plate, and the receipt of 510 clearances from the U.S. Food and Drug Administration for Modulus ALIF and Cohere® TLIF-O.

• NuVasive to Participate in BofA Securities 2020 Healthcare Conference

  5/4/2020

  NuVasive, Inc. announced that management will present at the virtual BofA Securities 2020 Healthcare Conference on Tuesday, May 12 at 5:00 p.m. ET/2:00 p.m. PT.

• NuVasive Provides Business Update Related to COVID-19

  4/14/2020

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today provided an update on actions the Company is taking to best position the business and support the Company's stakeholders in light of the COVID-19 pandemic.

• Randomized Controlled Trial Results Published in 'Spine' Demonstrate Efficacy of NuVasive Attrax® Putty in Posterolateral Lumbar Fusion

  3/10/2020

  Attrax Putty is now the first and only ceramic bone graft substitute supported by Level I evidence to demonstrate non-inferior fusion performance compared to autograft(1)

• DLA Piper advises NuVasive in its $450 million convertible senior notes offering and credit agreement amendment

  3/5/2020

   DLA Piper advised NuVasive, Inc., a San Diego -based medical device company that creates and distributes products for surgical treatment of spine disorders, in its offering of US$450 million aggregate principal amount of 0.375% convertible senior notes due 2025. NuVasive also granted to the initial purchasers of the convertible notes a

• NuVasive to Participate at Spine Summit 2020

  3/2/2020

  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate at Spine Summit 2020, the 36 th Annual Meeting of the Section on Disorders of the Spine and Peripheral Nerves on March 5-8, 2020

• NuVasive, Inc. Announces Pricing Of Offering Of $450 Million Of 0.375% Convertible Senior Notes Due 2025

  2/27/2020

  NuVasive, Inc. announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• NuVasive to Participate in Cowen 40th Annual Healthcare Conference

  2/27/2020

  NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced that management will present at the Cowen 40th Annual Healthcare Conference at The Boston Marriott Copley Place in Boston on Tuesday, March 3, 2020 at 9:20 a.m. ET/6:20 a.m. PT..

• NuVasive, Inc. Announces Proposed Offering Of $450 Million Of Convertible Senior Notes Due 2025

  2/26/2020

  SAN DIEGO , Feb. 26, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today that it intends to offer (the "Offering"), subject to market and other considerations, $450,000,000 aggregate principal amount of Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities

• NuVasive Announces Fourth Quarter and Full Year 2019 Financial Results

  2/20/2020

  NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced financial results for the quarter and full year ended Dec. 31, 2019.